Coronary interventions

A prospective multicentre randomised all-comers trial to assess the safety and effectiveness of the thin-strut sirolimus-eluting coronary stent SUPRAFLEX: rationale and design of the Thin Strut Sirolimus-eluting Stent in All Comers Population vs Everolimus-eluting Stent (TALENT) trial

EuroIntervention 2019;15:e362-e369. DOI: 10.4244/EIJ-D-18-00499

Rodrigo Modolo
Rodrigo Modolo1,2, MD; Ply Chichareon1,3, MD; Norihiro Kogame1, MD; Taku Asano1, MD; Chun-Chin Chang4, MD; Robbert J. de Winter1, MD, PhD; Upendra Kaul5, MD; Azfar Zaman6, MD; Ernest Spitzer4,7, MD; Kuniaki Takahashi1, MD; Yuki Katagiri1, MD; Osama I.I. Soliman4,7, MD, PhD; Gerrit A. van Es7, PhD; Marie-Angèle Morel7, BSc; Yoshinobu Onuma4,7, MD, PhD; Patrick W. Serruys8, MD, PhD; on behalf of the TALENT trial investigators
1. Department of Cardiology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands; 2. Department of Internal Medicine, Cardiology Division, University of Campinas (UNICAMP), Campinas, Brazil; 3. Division of Cardiovascular Medicine, Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Hatyai, Songkhla, Thailand; 4. Thoraxcenter, Erasmus University Medical Center, Rotterdam, the Netherlands; 5. Dean Academics and Research, Batra Hospital and Medical Research Center, New Delhi, India; 6. Freeman Hospital. Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom; 7. Cardialysis Clinical Trials Management and Core Laboratories, Rotterdam, the Netherlands; 8. Imperial College London, London, United Kingdom, United Kingdom

Aims: The aim of this study is to compare the SUPRAFLEX sirolimus-eluting stent (SES) with the XIENCE everolimus-eluting stent (EES) with respect to target lesion failure (TLF) at 12 months in a non-inferiority trial in a “real-world” patient population.

Methods and results: This is a prospective, randomised, 1:1 balanced, controlled, single-blind, multicentre study comparing clinical outcomes at 12 months between SUPRAFLEX and XIENCE in an “all-comers” patient population, comprising a total of 1,430 enrolled subjects with symptomatic coronary artery disease who qualify for percutaneous coronary interventions at 23 centres in Europe. The primary endpoint is a non-inferiority comparison of the device-oriented composite endpoint target lesion failure (cardiac death, target vessel myocardial infarction and clinically indicated target lesion revascularisation) of the SUPRAFLEX group to the XIENCE group at 12 months post procedure. Secondary endpoints include the patient-oriented composite endpoint, target vessel failure, mortality, myocardial infarction, revascularisation and stent thrombosis rates (ARC classification).

Conclusions: The TALENT trial aims to assess the safety and effectiveness of the thin-strut SUPRAFLEX compared to the current standard of care (XIENCE EES) in patients with atherosclerotic lesions. This will provide valuable information on the impact of this thin-strut device in an all-comers population.

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

acs/nste-acsdrug-eluting stentstable angina
Coronary interventionsStents and scaffolds
Read next article
Early strut protrusion and late neointima thickness in the Absorb bioresorbable scaffold: a serial wall shear stress analysis up to five years

Latest news